A Multicenter, Open-Label, Dose-Escalation, Phase 1 Study of TAK-441, an Oral Hedgehog Signaling Pathway Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies.
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2014
At a glance
- Drugs TAK 441 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2013 Planned End Date changed from 1 Sep 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 14 Sep 2012 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.